Clinical Trial

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).
Protocol Amendment History 1 change
minor Completion pushed: 2031-05 -> 2032-12 2026-07-02
Trial Details
NCT Number NCT07079631
Lead Sponsor BioNTech SE
Collaborators: Genmab
Conditions Metastatic Colorectal Cancer
Enrollment 482 participants
Start Date 2025-07-18
Primary Completion 2030-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01